Home    Back

Saracatinib    (DrugBank: Saracatinib)

3 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease1
89Lymphangioleiomyomatosis2
272Fibrodysplasia ossificans progressiva2

6. Parkinson disease    [ 2,123 clinical trials,   2,046 drugs,   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,123 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03661125
(ClinicalTrials.gov)		April 11, 20194/9/2018SRC Inhibition as a Potential Target for Parkinson's Disease PsychosisA Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis.Parkinson Disease PsychosisDrug: Saracatinib;Drug: Placebo Oral TabletKing's College LondonAstraZeneca;King's College Hospital NHS TrustRecruiting40 YearsN/AAll30Early Phase 1United Kingdom

89. Lymphangioleiomyomatosis    [ 38 clinical trials,   42 drugs,   (DrugBank: 19 drugs),   26 drug target genes,   134 drug target pathways]
Searched query = "Lymphangioleiomyomatosis", "LAM"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 38 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02737202
(ClinicalTrials.gov)		April 201631/3/2016Safety and Efficacy of Saracatinib In Subjects With LymphangioleiomyomatosisSafety and Efficacy of Saracatinib In Subjects With LymphangioleiomyomatosisPulmonary LymphangioleiomyomatosisDrug: saracatinibBaylor College of MedicineUniversity of Cincinnati;Brigham and Women's Hospital;Stanford University;Loyola University;University of South Florida;National Institutes of Health (NIH)Terminated18 Years65 YearsFemale28Phase 2United States
2NCT02116712
(ClinicalTrials.gov)		August 201415/4/2014The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)Pulmonary LymphangioleiomyomatosisDrug: SaracatinibTony EissaUniversity of Texas;University of CincinnatiCompleted18 Years65 YearsBoth9Phase 1United States

272. Fibrodysplasia ossificans progressiva    [ 23 clinical trials,   21 drugs,   (DrugBank: 4 drugs),   10 drug target genes,   87 drug target pathways]
Searched query = "Fibrodysplasia ossificans progressiva", "FOP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 23 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04307953
(ClinicalTrials.gov)		August 5, 202011/3/2020Saracatinib Trial TO Prevent FOPSaracatinib Trial TO Prevent FOPFibrodysplasia Ossificans ProgressivaDrug: AZD0530 Difumarate;Drug: Matching placeboVU University Medical CenterRoyal National Orthopaedic Hospital NHS Trust;Klinikum Garmisch-Patenkirchen;University of Oxford;Brigham and Women's Hospital;AstraZeneca;Innovative Medicines InitiativeRecruiting18 Years65 YearsAll20Phase 2Germany;Netherlands;United Kingdom
2EUCTR2019-003324-20-NL
(EUCTR)		08/01/202016/10/2019A clinical trial to judge the safety, tolerability and effects on abnormal bone formation of reseach medication AZD 0530 (sarcatinib) in patients with FOPSaracatinib trial TO Prevent FOP - STOPFOP Fibrodyplasia Ossificans Progressiva (FOP)
MedDRA version: 20.0;Level: PT;Classification code 10068715;Term: Fibrodysplasia ossificans progressiva;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]		Product Name: Saracatinib
Product Code: AZD0530
INN or Proposed INN: Saracatinib
Other descriptive name: SARACATINIB DIFUMARATE		VU University Medical CenterNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		16Phase 2Netherlands

Back to top